NK - ネクタ―・セラピュ―ティクス (NantKwest Inc.)

NKのニュース

   NantKwest Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of NantKwest, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NK  2020/12/24 15:08:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest shareholders. Under the terms of the agreement, ImmunityBio shareholders will receive a fixed exchange ratio of 0.8190 shares of NantKwest for each share of ImmunityBio owned. Upon completion of the transaction, ImmunityBio shareholders will own approximately 72% of the combined company and NantKwest shareholders
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of NantKwest, Inc. - NK  2020/12/24 02:00:00 PR Newswire
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating NantKwest, Inc. ("NK" or the "Company") (NK) relating to its…
   ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study  2020/11/10 12:00:00 Business Wire
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have administered their second-generation bivalent, human adenovirus (hAd5) COVID-19 vaccine candidate in a Phase 1 trial with no serious adverse events (SAE) reported in the low dose cohort, safety is ongoing for the high dose cohort. The trial, being conducted at
   NantKwest Names Richard Adcock Chief Executive Officer  2020/10/26 20:15:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven operational skills Richard Adcock as its Chief Executive Officer, effective immediately. Adcock brings extensive leadership experience to NantKwest as the company advances rapidly in the development of natural killer cell-based immunotherapies for cancer and serious infectious diseases. Rich will assume the r
   ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate Delivering Both Spike and Nucleocapsid of SARS-CoV-2  2020/10/21 21:06:00 Business Wire
CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that the first patient has been dosed in the Phase 1 clinical trial of hAd5-COVID-19, a novel COVID-19 vaccine candidate that targets the inner nucleocapsid (N) and the outer spike (S) protein, engineered to activate both T cells and antibodies against the coronavirus (S
   NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested  2020/06/10 13:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the publication of two peer-reviewed manuscripts in the Journal of Immunotherapy of Cancer. These invitro and in-vivo studies, conducted in collaboration with the National Cancer Institute pursuant to a Cooperative Research and Development Agreement, support the mechanism and functionality of NantKwest’s clinical-stage engineered natural killer (NK
   The race for coronavirus treatments and vaccines is heating up. Here are the 12 most important events to watch for in June, from fresh vaccine data to new antibody drug trials.  2020/06/01 12:25:00 Business Insider
The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to watch for this month, including new drugs and vaccines starting human testing and a range of data readouts from ongoing studies. The catalysts will impact drug companies ranging in size from massive to tiny, including biopharma giants like Eli Lilly and Regeneron and small biotechs like NantKwest and Inovio Pharmaceuticals. Visit Business Insider's homepage for more stories . June is shaping up to be a critical month for several coronavirus treatment and vaccine research programs. Some will start human testing for the first time, while others will wrap up and report results from clinical trials. There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people.
   NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates  2020/05/27 17:56:10 Benzinga
Nantkwest Inc (NASDAQ: NK ) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options. Vaccine Program Part Of ‘Operation Warp Speed' El Segundo, California-based NantKwest said its affiliate ImmunityBio has been selected to participate in Operation Warp Speed , a national program aimed at providing substantial quantities of safe, effective vaccine for Americans by January 2021. NanKwest said it will focus on developing, testing and largescale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate, codenamed hAd5. The company said it's the first vaccine designed to deliver both Spike and Nucleocapsid DNA, offering scope for long-lasting immunity. "ImmunityBio is honored to have been selected as one of the 14 companies for Operation Warp Speed and is committed to moving our … Full story available on Benzinga.com
   ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine  2020/05/27 16:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-
   NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 13:30:00 Business Wire
EL SEGUNDO, Calif.,--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days. About NantKwe
   The race for coronavirus treatments and vaccines is heating up. Here are the 12 most important events to watch for in June, from fresh vaccine data to new antibody drug trials.  2020/06/01 12:25:00 Business Insider
The race for coronavirus treatments and vaccines is expected to maintain its frenetic pace in June. Business Insider identified the 12 top events to watch for this month, including new drugs and vaccines starting human testing and a range of data readouts from ongoing studies. The catalysts will impact drug companies ranging in size from massive to tiny, including biopharma giants like Eli Lilly and Regeneron and small biotechs like NantKwest and Inovio Pharmaceuticals. Visit Business Insider's homepage for more stories . June is shaping up to be a critical month for several coronavirus treatment and vaccine research programs. Some will start human testing for the first time, while others will wrap up and report results from clinical trials. There's no shortage of activity in hunting for pharmaceutical solutions to COVID-19, the disease caused by the novel coronavirus. The World Health Organization has tallied 125 coronavirus vaccine programs. Several hundred experimental drugs are being looked at to treat infected people.
   NantKwest Vaccine Now Part Of 'Operation Warp Speed,' Lays Out Plan For COVID-19 Candidates  2020/05/27 17:56:10 Benzinga
Nantkwest Inc (NASDAQ: NK ) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options. Vaccine Program Part Of ‘Operation Warp Speed' El Segundo, California-based NantKwest said its affiliate ImmunityBio has been selected to participate in Operation Warp Speed , a national program aimed at providing substantial quantities of safe, effective vaccine for Americans by January 2021. NanKwest said it will focus on developing, testing and largescale manufacturing of ImmunityBio's COVID-19 human adenovirus vaccine candidate, codenamed hAd5. The company said it's the first vaccine designed to deliver both Spike and Nucleocapsid DNA, offering scope for long-lasting immunity. "ImmunityBio is honored to have been selected as one of the 14 companies for Operation Warp Speed and is committed to moving our … Full story available on Benzinga.com
   ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine  2020/05/27 16:00:00 Business Wire
EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected to participate in Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021. Efforts will focus on the development, testing, and large-scale manufacturing of ImmunityBio’s COVID-
   NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference  2020/05/26 13:30:00 Business Wire
EL SEGUNDO, Calif.,--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days. About NantKwe
   Be The Match BioTherapies and NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 Deaths  2020/05/19 12:00:00 Business Wire
MINNEAPOLIS & EL SEGUNDO, Calif.--(BUSINESS WIRE)--Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b trial to address one of the primary causes of COVID-19 deaths.

calendar